Cargando…

Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT

BACKGROUND: Pharmacogenomic testing guided treatment have been developed to guide drug selection or conversion in major depressive disorder patients. Whether patients benefit from pharmacogenetic testing remains unclear. We aim to evaluates the effect of pharmacogenomic testing guiding on clinical o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xinrui, Wang, Chenfei, Zhang, Yi, An, Zhuoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176803/ https://www.ncbi.nlm.nih.gov/pubmed/37173736 http://dx.doi.org/10.1186/s12888-023-04756-2

Ejemplares similares

251 A Mixed Methods Study of Patient and Clinician Views and Experiences of Pharmacogenomic Testing for Major Depressive Disorder
por: Hendy, Katherine, et al.
Publicado: (2023)

The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
por: Saya, Sibel, et al.
Publicado: (2023)

Effects of body-oriented yoga: a RCT study for patients with major depressive disorder
por: Bieber, Miriam, et al.
Publicado: (2021)

Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study
por: Del Casale, Antonio, et al.
Publicado: (2022)

Using a pharmacogenomic algorithm to guide the treatment of depression
por: Hall-Flavin, D K, et al.
Publicado: (2012)

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials
por: Brown, Lisa C., et al.
Publicado: (2022)

Pharmacogenomic Testing for Major Depression: A Qualitative Study of the Perceptions of People with Lived Experience and Professional Stakeholders
por: Slomp, Caitlin, et al.
Publicado: (2022)

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Pharmacogenomics in depression and antidepressants
por: Bondy, Brigitta
Publicado: (2005)

Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix(®)) to Guide Treatment of Patients with Depression and/or Anxiety
por: Najafzadeh, Mehdi, et al.
Publicado: (2017)

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
por: Ji, Yuan, et al.
Publicado: (2012)

Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
por: Groessl, Erik J., et al.
Publicado: (2018)

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
por: Zhu, Ye, et al.
Publicado: (2019)

Systematic reviews and meta-analyses on major depressive disorder: a bibliometric perspective
por: Chen, Pan, et al.
Publicado: (2023)

Pharmacogenomic testing and outcome among depressed patients in a tertiary care outpatient psychiatric consultation practice
por: Rundell, J R, et al.
Publicado: (2011)

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
por: Wigle, Theodore J., et al.
Publicado: (2017)

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2018)

Development and Implementation of In-House Pharmacogenomic Testing Program at a Major Academic Health System
por: Mroz, Pawel, et al.
Publicado: (2021)

An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis
por: David, Victoria, et al.
Publicado: (2021)

Strategies to Improve the Clinical Outcomes for Direct-to-Consumer Pharmacogenomic Tests
por: Tafazoli, Alireza, et al.
Publicado: (2021)

Pharmacogenomics of Leukotriene Modifiers: A Systematic Review and Meta-Analysis
por: Zhao, Yuxuan, et al.
Publicado: (2022)

Epidemiology of Major Depressive Disorder in Iran: a Systematic Review and Meta-Analysis
por: Sadeghirad, Behnam, et al.
Publicado: (2010)

Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis
por: Kennis, Mitzy, et al.
Publicado: (2019)

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
por: Zhang, Xinyan, et al.
Publicado: (2022)

Effectiveness of family psychoeducation for major depressive disorder: systematic review and meta-analysis
por: Katsuki, Fujika, et al.
Publicado: (2022)

Effectiveness of yoga for major depressive disorder: A systematic review and meta-analysis
por: Wu, Yufei, et al.
Publicado: (2023)

Physical exercise and major depressive disorder in adults: systematic review and meta-analysis
por: Pérez Bedoya, Édison Andrés, et al.
Publicado: (2023)

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2020)

Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?
por: Pearson, Ewan R.
Publicado: (2019)

Personalized antihypertensive treatment guided by pharmacogenomics in China
por: Xiao, Zhi-Lin, et al.
Publicado: (2022)

Pharmacogenomics in practice: a review and implementation guide
por: Kabbani, Danya, et al.
Publicado: (2023)

Predictors of Electroconvulsive Therapy Outcome in Major Depressive Disorder
por: Su, Liang, et al.
Publicado: (2022)

Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis
por: Teng, Teng, et al.
Publicado: (2022)

Prevalence of Major Depressive Disorder Among Adults in China: A Systematic Review and Meta-Analysis
por: Zhao, Yan-Jie, et al.
Publicado: (2021)

Psychiatric pharmacogenomic testing in clinical practice
por: Mrazek, David A.
Publicado: (2010)

Overview of pharmacogenomic testing in clinical practice
por: Gross, Tonya, et al.
Publicado: (2018)

The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report
por: Matteo, Marcatili, et al.
Publicado: (2021)

Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy
por: Roosan, Don, et al.
Publicado: (2020)

Patient Perspectives of Barriers and Facilitators for the Uptake of Pharmacogenomic Testing in Veterans Affairs’ Pharmacogenomic Testing for the Veterans (PHASER) Program
por: Melendez, Karina, et al.
Publicado: (2023)

Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis
por: Islam, Farhana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l5s1gb270pivf83cqhd3bbvsu9